Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$303 Mln
Revenue (TTM)
$73 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.5
Industry P/E
--
EV/EBITDA
-2.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$8.8
EPS
$-3.2
Face value
--
Shares outstanding
50,269,082
CFO
$-246.73 Mln
EBITDA
$-458.73 Mln
Net Profit
$-493.47 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bicycle Therapeutics - ADR
| -28.7 | -11.9 | -28.7 | -35.7 | -38.1 | -30.2 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Bicycle Therapeutics - ADR
| -49.4 | -22.4 | -38.9 | -51.4 | 239.1 | 90.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bicycle Therapeutics - ADR
|
5.1 | 302.5 | 72.6 | -219.0 | -318.2 | -31.2 | -- | 0.5 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include... zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Address: Portway Building, Cambridge, United Kingdom, CB21 6GS Read more
CEO & Executive Director
Dr. Kevin Lee M.B.A., Ph.D.
CEO & Executive Director
Dr. Kevin Lee M.B.A., Ph.D.
Headquarters
Cambridge
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Bicycle Therapeutics plc - ADR is $5.05 (NASDAQ) as of 02-Apr-2026 17:29 EDT. Bicycle Therapeutics plc - ADR has given a return of -38.08% in the last 3 years.
Since, TTM earnings of Bicycle Therapeutics plc - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.23
|
0.80
|
|
2024
|
-4.80
|
1.02
|
|
2023
|
-3.60
|
1.75
|
|
2022
|
-7.88
|
3.28
|
|
2021
|
-22.77
|
4.39
|
The 52-week high and low of Bicycle Therapeutics plc - ADR are Rs 9.55 and Rs 4.24 as of 05-Apr-2026.
Bicycle Therapeutics plc - ADR has a market capitalisation of $ 303 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Bicycle Therapeutics plc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.15
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.